Actively Recruiting
Empagliflozin Reversal of Arterial StiffnEss in Aging
Led by University of Missouri-Columbia · Updated on 2026-02-06
80
Participants Needed
1
Research Sites
236 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
CONDITIONS
Official Title
Empagliflozin Reversal of Arterial StiffnEss in Aging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide consent
- 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
- Stable anti-hypertensive medication regimen (if in use) for at least 90 days
- Evidence of arterial stiffening (defined as carotid-femoral PWV >= 8 m/s) at the time of screening visit.
You will not qualify if you...
- Diabetes
- BMI >= 45kg/m2
- Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
- Estimated glomerular filtration rate GFR < 29 mL/min
- Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
- Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
- Use of hormone replacement therapy
- Body weight change 610% within the last 6 months
- Uncontrolled hypertension during screening visit (>180/110 mmHg)
- Symptomatic hypotension and/or a SBP <100 mmHg
- History of ketoacidosis
- High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)
- Anticipated need of prolonged fasting
- History of recurrent UTIs or mycotic genital infections
- Following a low-carbohydrate diet (<20 grams/day)
- Participation in regular exercise > 3 days/week per week at a moderate or vigorous intensity
- Known sensitivity to nitrate medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Missouri
Columbia, Missouri, United States, 65211
Actively Recruiting
Research Team
C
Camila Manrique, MD
CONTACT
A
Andrea Atkins, BSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here